Applied Chemical Engineering

Functional Role of Female Sex Hormones and Receptors in Cervical Carcinoma

Sura Basil Findakly

Mustansiriyah University

Rasha Hamza Mnehil

Al Elwiya maternity hospital, ministry of health, Baghdad, Iraq

Kawakeb N. A. Abdullae

Iraqi National Cancer Research Centre, University of Baghdad, Baghdad, Iraq*

Montadher Ali Mahdi

Iraqi National Cancer Research Centre, University of Baghdad, Baghdad, Iraq*

DOI: https://doi.org/10.59429/ace.v9i1.5894

Keywords: Cervical carcinoma; estrogen receptor alpha; progesterone receptor; sex hormone; SHBG, DHEAS; estradiol

---

Abstract

Cervical carcinoma remains one of the most prevalent malignancies affecting women worldwide. While human papillomavirus (HPV) infection is a well-established etiological factor, growing evidence suggests that female sex hormones and their receptors may significantly influence the pathogenesis and progression of cervical cancer. Hormonal imbalances, particularly involving estrogen and progesterone, may impact tumor growth and immune modulation within the tumor microenvironment. This study investigates the functional role of selected female sex hormones and their corresponding receptors in Iraqi women diagnosed with cervical carcinoma. A total of 60 female participants were enrolled from gynecology and oncology departments in Baghdad and Karbala, Iraq. Thirty women with histologically confirmed cervical carcinoma were assigned to the patient group, while thirty age-matched healthy volunteers served as controls. Blood samples were collected under fasting conditions, and serum levels of sex hormone-binding globulin (SHBG), estradiol (E2), dehydroepiandrosterone sulfate (DHEAS), progesterone, estrogen receptor alpha (ERα), and progesterone receptor (PR) were quantified using standardized ELISA kits. Statistical comparisons were conducted using SPSS with significance set at p < 0.05. Significant hormonal differences were observed between patient and control groups. Estradiol levels were markedly lower in postmenopausal patients than in premenopausal patients, while DHEAS levels were significantly higher in the same comparison. SHBG and DHEAS levels were also elevated in patients compared to controls. Importantly, ERα levels were significantly decreased, while PR levels were significantly increased in cervical cancer patients relative to controls. A strong association was observed between cervical cancer diagnosis and positive family history (73.3% in patients vs. 13% in controls). Our findings suggest that imbalances in circulating sex hormones and alterations in receptor expression—particularly reduced ERα and elevated PR, may contribute to cervical carcinogenesis. These hormonal and biochemical signatures, alongside potential hereditary patterns, highlight the importance of incorporating hormonal profiling in the clinical evaluation of cervical cancer. Further research is warranted to explore the therapeutic potential of targeting hormone receptor pathways in cervical cancer management.

---

References

[1]. Mahdi, M. A., Dawood, Y. J., Jumaa, A. H., Abod, K. S., & Manssor, K. J. (2026). From ROS to Tumorigenesis: Understanding the Oxidative Pathways in Cervical Cancer Progression. Asian Pacific Journal of Cancer Biology, 11(1), 259-266.‏

[2]. A. Albayrak, A. Unlu, N. Calik, A. Capar et al., "A Whole Slide Image Grading Benchmark and Tissue Classification for Cervical Cancer Precursor Lesions with Inter-Observer Variability," 2018. [PDF]

[3]. Dawood, Y. J., Saad, R., Mahdi, M. A., & Jumaa, A. H. (2025). Evaluation of LDH, AFP, β-hCG and Tumour Markers CEA and CA-125 in Sera of Iraqi Patients With Ovarian Cancer. Scripta Medica, 56(2), 275-282.‏

[4]. R. Polten, I. Kutle, J. Hachenberg, R. Klapdor et al., "Towards Novel Gene and Cell Therapy Approaches for Cervical Cancer," 2022. ncbi.nlm.nih.gov

[5]. N. Stastna, K. Brat, L. Homola, A. Os et al., "Increasing incidence rate of breast cancer in cystic fibrosis - relationship between pathogenesis, oncogenesis and prediction of the treatment effect in the context of worse clinical outcome and prognosis of cystic fibrosis due to estrogens," 2023. ncbi.nlm.nih.gov

[6]. M. Läsche, J. Gallwas, and C. Gründker, "Like Brothers in Arms: How Hormonal Stimuli and Changes in the Metabolism Signaling Cooperate, Leading HPV Infection to Drive the Onset of Cervical Cancer," 2022. ncbi.nlm.nih.gov

[7]. M. Bächler, D. Menshykau, C. De Geyter, and D. Iber, "Species-specific differences in follicular antral sizes result from diffusion-based limitations on the thickness of the granulosa cell layer," 2013. [PDF]

[8]. M. del-Valle, E. Soares Bernardes, and D. Maria Zezell, "Dual-path convolutional neural network using micro-FTIR imaging to predict breast cancer subtypes and biomarkers levels: estrogen receptor, progesterone receptor, HER2 and Ki67," 2023. [PDF]

[9]. A. C. Bovo, P. G. Pedrão, Y. M. Guimarães, "Combined Oral Contraceptive Use and the Risk of Cervical Cancer: Literature Review," Revista Brasileira de, 2023. thieme-connect.com

[10]. S. A. Lee, S. Baik, and S. H. Chung, "Functional roles of female sex hormones and their nuclear receptors in cervical cancer," Essays in biochemistry, 2021. nih.gov

[11]. S. Tripathy, S. Nallasamy, and M. Mahendroo, "Progesterone and its receptor signaling in cervical remodeling: mechanisms of physiological actions and therapeutic implications," The Journal of Steroid …, Elsevier, 2022. sciencedirect.com

[12]. Dawood, Y. J., Mahdi, M. A., Jumaa, A. H., Saad, R., & Khadim, R. M. (2024). Evaluation of LH, FSH, oestradiol, prolactin and tumour markers CEA and CA-125 in sera of Iraqi patients with endometrial cancer. Scripta Medica, 55(4), 419-426.‏

[13]. Muñoz, N., et al. (2006). "Epidemiologic classification of human papillomavirus types associated with cervical cancer." New England Journal of Medicine, 348(6), 518-527.

[14]. Plummer, M., et al. (2003). "Smoking and cervical cancer: pooled analysis of the IARC multi-centric case–control study." Cancer Causes & Control, 14(9), 805-814.

[15]. Mahdi, M. A., Dawood, Y. J., Sabah, R. S., & Abd Al-Rahman, S. (2024). Evaluation of oxidative stress, anti-oxidant, vitamins and co-factor elements in the sera of gastric cancer in Iraqi patients. Asian Pacific journal of cancer prevention: APJCP, 25(10), 3651.‏

[16]. Stanczyk, F. Z., et al. (2006). "Cervical cancer and hormones." Annals of the New York Academy of Sciences, 1089(1), 286-298.

[17]. Y. Taay, M. Mohammed, R. Abbas, A. Ayad, and M. Mahdi, "Determination of some biochemical parameters in sera of normotensive and hypertensive obese female in Baghdad," in Journal of Physics: Conference Series, 2021, vol. 1853, no. 1: IOP Publishing, p. 012037.

[18]. Cheng, Y., et al. (2016). "Estrogen receptor α affects the prognosis of cervical cancer through the PI3K/AKT pathway." Archives of Gynecology and Obstetrics, 294(1), 59-68.

[19]. Mahdi, M. A., Jumaa, A. H., & Dawood, Y. J. (2025). Clinical Investigation of IL-31, TOS and GSH in the Sera of Gastric Cancer Females Patients In Iraq. Asian Pacific Journal of Cancer Prevention: APJCP, 26(2), 587.‏

[20]. S. Mitra, M. S. Lami, A. Ghosh, R. Das, T. E. Tallei et al., "Hormonal therapy for gynecological cancers: how far has science progressed toward clinical applications?," Cancers, 2022. mdpi.com

[21]. A. Gadducci, S. Cosio, and F. Fruzzetti, "Estro-progestin contraceptives and risk of cervical cancer: a debated issue," Anticancer Research, 2020. iiarjournals.org

[22]. Smith, I. E., & Dowsett, M. (2003). "Aromatase inhibitors in breast cancer." New England Journal of Medicine, 348(24), 2431-2442.